Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6077979 | 0.98 | CYP1A2 (0.56) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL13965846 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL11089154 | 0.83 | CYP1A2 (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL1566716 | 0.82 | POLB (0.56) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL13965850 | 0.82 | IDO1 (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL13995324 | 0.80 | CHRM2 (0.58) | MEN1KMT2AL3MBTL1KCNH2TMEM97 | |
| SCHEMBL18768914 | 0.80 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL8987672 | 0.79 | L3MBTL1 (0.65) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL23583427 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT | |
| SCHEMBL11932565 | 0.79 | HRH4 (0.47) | CYP1A2CYP2D6CYP2C9CYP2C19PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363288-B1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR MOSSES | CUREARTH INC (KR) | 2022-09-07 | — | — | EP | disclosed |
| CN-108347925-B | Compositions for destroying microalgae or moss | 株式会社CUREARTH | 2021-07-16 | — | — | CN | disclosed |
| US-11044909-B2 | Composition for destruction of microalgae or sphaerocarpus | CUREARTH, INC. (KR) | 2021-06-29 | — | — | US | disclosed |
| US-11044909-B2 | Composition for destruction of microalgae or sphaerocarpus | CUREARTH, INC. (KR) | 2021-06-29 | — | — | US | disclosed |
| US-20180271091-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | CUREARTH, INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| EP-3363288-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | Curearth, Inc. (KR) | 2018-08-22 | — | — | EP | disclosed |
| CN-108347925-A | composition for destroying microalgae or moss | 株式会社CUREARTH | 2018-07-31 | — | — | CN | disclosed |
| WO-2017065401-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | 주식회사 큐얼스 | 2017-04-20 | — | — | WO | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | CYP1A2 483/4885CYP2D6 1226/4885CYP2C9 1555/4885 |
| US-20180271091-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | TK1, TRHDE, TK2 | CYP1A2 4399/4885CYP2D6 4332/4885CYP2C9 4640/4885 |
| US-11044909-B2 | Composition for destruction of microalgae or sphaerocarpus | TK1, TRHDE, TK2 | CYP1A2 4399/4885CYP2D6 4332/4885CYP2C9 4640/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CYP1A2 1189/4885CYP2D6 790/4885CYP2C9 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.